Intra-osseous UCB and hMSC Co-transplant for Hematologic Malignancies

Phase 1, open-label, single-arm trial of umbilical cord blood and Provacel in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 5 more, sponsored by Case Comprehensive Cancer Center. Primary endpoints: Number of patients with BM cellularity failure at 42 days, Number of patients with ANC failure without evidence of disease at 42 days and 1 more. Started Jul 2015; status: completed.